Text Size

Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea

This study has been completed.
Sponsor:
Information provided by:
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00455858
First received: April 3, 2007
Last updated: June 26, 2012
Last verified: June 2012
History of Changes
Results First Received: December 16, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Diabetes
Diabetes Mellitus, Type 2
Intervention: Drug: insulin detemir

  Participant Flow
  Show Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Insulin Detemir Insulin detemir start dose of 0.2 U/kg body weight added to Subject's ongoing OAD (oral anti-diabetic drug) monotherapy or combination therapy of 2 or more OADs. Insulin detemir treatment is titrated based on subject's self-monitored plasma glucose.

Baseline Measures
    Insulin Detemir  
Number of Participants  
[units: participants]
 		  87  
Age  
[units: years]
Mean ± Standard Deviation 		  55.7  ± 9.5  
Gender  
[units: participants]
 		 
Female     51  
Male     36  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20   [ Time Frame: week 0, week 20 ]
  Show Outcome Measure 1

2.  Secondary:   Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 12   [ Time Frame: week 0, week 12 ]
  Show Outcome Measure 2

3.  Secondary:   Change in Fasting Plasma Glucose (FPG)   [ Time Frame: week 0, week 12, week 20 ]
  Show Outcome Measure 3

4.  Secondary:   Percentage of Subjects Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7.0%   [ Time Frame: week 12, week 20 ]
  Show Outcome Measure 4

5.  Secondary:   Occurence of Hypoglycaemic Episodes   [ Time Frame: weeks 0-20 ]
  Show Outcome Measure 5


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Public Access to Clinical Trials
Organization: Novo Nordisk A/S
e-mail: clinicaltrials@novonordisk.com


No publications provided


Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00455858     History of Changes
Other Study ID Numbers: NN304-1762
Study First Received: April 3, 2007
Results First Received: December 16, 2009
Last Updated: June 26, 2012
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)